婦人科治療薬の世界市場レポート 2025年

婦人科治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.8%で、570億8,000万米ドルに成長します。予測期間における成長の背景には、避妊薬やホルモン補充療法（HRT）に対する認識と使用の増加、加齢に伴う婦人科系がんの増加、卵巣がんの増加、婦人科系疾患の流行、ヘルスケア支出の増加、子宮内膜症のメカニズム解明とその治療のための投資の増加があります。予測期間における主な動向としては、企業は腫瘍や子宮内膜症の患者を治療し、生存期間を延長させるために、新たな治療開発の立ち上げや採用を検討すべきであり、より良い治療選択肢を提供するために新たな更年期ホルモン療法の開発に注力すべきであり、新薬の創出・開発の新たな機会を生み出す婦人科治療薬研究への投資が挙げられる、卵巣がんをターゲットとした抗体薬物複合体（ADC）標的治療薬の開発、製品ポートフォリオを拡大するための戦略的共同研究やパートナーシップの締結の検討、収益の向上とカテゴリー・リーダーシップの確立、薬剤耐性を克服し従来のがん治療による罹患率や死亡率を低下させるための併用療法への注力などです。

卵巣がんに罹患する女性の増加が予想されることから、世界の婦人科治療薬市場の成長が見込まれます。女性の生殖器官の一部である卵巣に発生する卵巣がんは、標的治療の選択肢を提供し、生存率を向上させ、患者の生活の質を高める婦人科治療薬によって効果的に管理されます。Globocanの推計によると、卵巣がんの世界発生率は2040年までに434,184人に達すると予測されており、そのため婦人科治療薬の需要が当面高まることになります。

加齢は、糖尿病、肥満、神経変性疾患、がんなど、さまざまな疾患の重大な危険因子となります。特に、初潮が早かったり閉経が遅かったりといった女性の生殖周期の乱れは、ホルモンバランスの乱れの一因となり、人生の後半におけるがんのリスクを高める。子宮内膜がんと卵巣がんは高齢女性に多く、かなりの死亡率に寄与しています。これらのがんの罹患率は年齢とともに上昇し、通常60～70歳頃にピークを迎えます。さらに、子宮頸がんは一般的に50歳前後で診断され、膣がんと外陰がんは一般的に遅く67歳前後で診断されます。例えば、米国がん協会は、2022年に米国で新たに子宮頸がんが14,000人発生すると推定しています。婦人科系がんの加齢に伴う増加は、今後数年間で市場を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界婦人科治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の婦人科治療薬市場：成長率分析
• 世界の婦人科治療薬市場の実績：規模と成長, 2019-2024
• 世界の婦人科治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界婦人科治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の婦人科治療薬市場セラピューティクス、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン療法
• 非ホルモン療法
• 世界の婦人科治療薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 婦人科がん
• 更年期障害
• 多嚢胞性卵巣症候群
• 避妊
• その他の適応症
• 世界の婦人科治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の婦人科治療薬市場ホルモン療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• エストロゲン補充療法
• プロゲステロン療法
• 併用ホルモン療法
• 世界の婦人科治療薬市場、非ホルモン療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗うつ薬（更年期障害の治療薬）
• 非ホルモン性抗けいれん薬
• ハーブと栄養補助食品

第7章 地域別・国別分析

• 世界の婦人科治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の婦人科治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 婦人科治療薬市場：競合情勢
• 婦人科治療薬市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Overview, Products and Services, Strategy and Financial Analysis
  • Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ferring Holding SA
• TherapeuticsMD Inc.
• Lupin Pharmaceuticals Inc.
• Johnson & Johnson
• Eli Lilly and Company
• Bayer AG
• Abbott Laboratories Ltd.
• AstraZeneca
• Amgen Inc.
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Allergan plc
• Sanofi S.A.
• Coloplast A/S
• Cipla Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 婦人科治療薬市場2029：新たな機会を提供する国
• 婦人科治療薬市場2029：新たな機会を提供するセグメント
• 婦人科治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gynecology drugs pertain to the medical field specializing in the treatment of illnesses affecting the female reproductive system, encompassing care for women during pregnancy and childbirth. These drugs serve the purpose of treating various gynecological diseases that may impact the uterus, ovaries, and appendages.

The primary therapeutic categories within gynecology drugs include hormonal therapy and non-hormonal therapy. Hormonal therapy involves treatments that either add, block, or remove hormones to impede the growth of cancer cells reliant on hormones for their development. Non-hormonal therapy includes the use of anti-infective and anti-inflammatory agents, lubricants, moisturizers, as well as medications such as antidepressants, gabapentin, clonidine, among others. Gynecology drugs find application in treating conditions such as gynecological cancers, menopausal disorders, polycystic ovary syndrome, contraception, and more. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The gynecology drugs market research report is one of a series of new reports from The Business Research Company that provides gynecology drugs market statistics, including gynecology drugs industry global market size, regional shares, competitors with a gynecology drugs market share, detailed gynecology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. This gynecology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gynecology drugs market size has grown strongly in recent years. It will grow from $43.27 billion in 2024 to $45.52 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to a rise in the introduction of drugs with novel mechanisms, a rise in educational tools and awareness on menopause, a rise in long-acting reversible contraceptives, a shift in lifestyles, a rise in healthcare awareness and expenditure, government initiatives and an increase in pharmaceutical R&D expenditure.

The gynecology drugs market size is expected to see strong growth in the next few years. It will grow to $57.08 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to an increase in awareness and use of contraceptives and hormone replacement therapy (HRT), an age-related increase in gynecological cancers, a rise in ovarian cancer, prevalence of gynecological diseases, a rise in healthcare expenditure and rising investment to understand the mechanisms of endometriosis and its treatment. Major trends in the forecast period include companies should consider launching or adopting new treatment developments to treat patients with oncology and endometriosis and give them a longer survival time, focus on the development of new menopausal hormone therapy to offer better treatment options, investments in gynecology drugs research that will create new opportunities to create and develop new drugs, increase awareness about benefits of contraceptives and launch new products into the market to fulfill the unmet need from developed and developing countries, develop antibody-drug conjugates (ADCs) targeted therapies to target ovarian cancers, consider entering into strategic collaborations and partnerships to broaden their product portfolios, boost revenues and establish category leadership and focus on combination therapies to overcome drug resistance and reduce morbidity and mortality caused due to traditional cancer treatments.

The anticipated increase in the number of women affected by ovarian cancer is expected to drive growth in the global gynecological drugs market. Ovarian cancer, originating in the ovaries as part of the female reproductive system, is effectively managed by gynecological drugs that offer targeted treatment options, improved survival rates, and enhanced quality of life for patients. According to estimates from Globocan, the global incidence of ovarian cancer is projected to reach 434,184 by 2040, thereby fostering the demand for gynecological drugs in the foreseeable future.

Age serves as a significant risk factor for various diseases, including diabetes, obesity, neurodegenerative disorders, and cancer. In particular, disruptions in female reproductive cycles, such as early menarche or late menopause, contribute to hormonal imbalances and increase the risk of cancer in later stages of life. Endometrial and ovarian cancers are prevalent among elderly women and contribute to substantial mortality rates. The incidence of these cancers rises with age, typically peaking around 60 to 70 years. Additionally, cervical cancer is commonly diagnosed around the age of 50, while vaginal and vulvar cancers are typically diagnosed later, around the age of 67. For instance, the American Cancer Society estimates 14,000 new cases of cervical cancer in the United States in 2022. The age-related upswing in gynecological cancers is expected to propel the market in the coming years.

Major companies in the gynecology drug market are focusing on the development of innovative medications, such as hormonal therapies, to address moderate to severe pain associated with endometriosis. Hormonal medications are drugs that contain hormones or hormone-like substances used to regulate or alter hormonal levels in the body for various conditions, including hormone replacement therapy, birth control, and endocrine disorders. For example, in August 2022, Myovant Sciences, a US-based biotechnology research company, and Pfizer, a US pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for managing moderate to severe pain linked to endometriosis. Endometriosis is a painful condition characterized by tissue similar to the uterine lining growing outside the uterus, affecting millions of women worldwide. The approval of MYFEMBREE marks a significant advancement in treatment options for this condition, offering a new oral medication that combines hormonal therapy with a GnRH antagonist. Overall, the direction of the gynecology drug market underscores a commitment to addressing the unique healthcare needs of women, ensuring they have access to the best available treatments.

Major companies in the gynecology drug market are focusing on developing innovative therapies, such as hormone replacement therapy (HRT), to gain a competitive advantage. HRT is a medical treatment that involves administering hormones to alleviate menopause symptoms, including hot flashes, night sweats, mood swings, and vaginal dryness, thereby enhancing the overall quality of life for women undergoing these changes. For example, in April 2023, the Department of Health and Social Care in the UK, in collaboration with NHS England and the NHS Business Services Authority, launched a new HRT prescription prepayment certificate (PPC). This initiative allows women in England to access HRT for only £19.30 per year (approximately $24.50 USD), significantly easing the financial burden of managing menopause symptoms.

In March 2022, Carlyle, a U.S.-based private equity firm, and PAI Partners, a France-based private equity firm, reached an agreement to acquire Theramex from CVC Capital Partners for $1.4 billion. This acquisition is intended to expand the investment portfolio of Carlyle and PAI in Theramex, focusing on organic, inorganic, and international growth initiatives. Theramex, a UK-based pharmaceutical company, specializes in women's health products related to fertility, contraception, menopause, and osteoporosis.

Major companies operating in the gynecology drugs market include Merck & Co. Inc., AbbVie, Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Ferring Holding SA, TherapeuticsMD Inc., Lupin Pharmaceuticals Inc., Johnson & Johnson, Eli Lilly and Company, Bayer AG, Abbott Laboratories Ltd., AstraZeneca, Amgen Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Allergan plc, Sanofi S.A., Coloplast A/S, Cipla Limited, Endo International PLC, Glenmark Pharmaceuticals Limited, S.K. Chemicals Co. Ltd., Dong A Pharmaceutical Co., Novartis AG, Furukawa Electric, Motherson Sumi, LS Cables & Systems, HUBER+SUHNER, Acome, Yazaki Corporation, Fujikura Ltd., Robert Bosch, HELLA GmbH & Co. KGaA, Coroplast Harness Technology Sp. z o.o.

North America was the largest region in the gynecology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gynecology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The gynecology market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gynecology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gynecology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gynecology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gynecology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Hormonal Therapy, Non-Hormonal Therapy
• 2) By Indication: Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, Other Indications
• 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• Subsegments:
• 1) By Hormonal Therapy: Estrogen Replacement Therapy; Progesterone Therapy; Combination Hormonal Therapy
• 2) By Non-Hormonal Therapy: Antidepressants (For menopausal symptoms); Non-Hormonal Anticonvulsants; Herbal And Dietary Supplements
• Companies Mentioned: Merck & Co. Inc.; AbbVie; Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gynecology Drugs Market Characteristics

3. Gynecology Drugs Market Trends And Strategies

4. Gynecology Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Gynecology Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gynecology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gynecology Drugs Market Growth Rate Analysis
• 5.4. Global Gynecology Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gynecology Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gynecology Drugs Total Addressable Market (TAM)

6. Gynecology Drugs Market Segmentation

• 6.1. Global Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapy
• Non-Hormonal Therapy
• 6.2. Global Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gynecology Cancers
• Menopausal Disorder
• Polycystic Ovary Syndrome
• Contraception
• Other Indications
• 6.3. Global Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Gynecology Drugs Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Replacement Therapy
• Progesterone Therapy
• Combination Hormonal Therapy
• 6.5. Global Gynecology Drugs Market, Sub-Segmentation Of Non-Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants (For menopausal symptoms)
• Non-Hormonal Anticonvulsants
• Herbal And Dietary Supplements

7. Gynecology Drugs Market Regional And Country Analysis

• 7.1. Global Gynecology Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gynecology Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gynecology Drugs Market

• 8.1. Asia-Pacific Gynecology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gynecology Drugs Market

• 9.1. China Gynecology Drugs Market Overview
• 9.2. China Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gynecology Drugs Market

• 10.1. India Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gynecology Drugs Market

• 11.1. Japan Gynecology Drugs Market Overview
• 11.2. Japan Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gynecology Drugs Market

• 12.1. Australia Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gynecology Drugs Market

• 13.1. Indonesia Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gynecology Drugs Market

• 14.1. South Korea Gynecology Drugs Market Overview
• 14.2. South Korea Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gynecology Drugs Market

• 15.1. Western Europe Gynecology Drugs Market Overview
• 15.2. Western Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gynecology Drugs Market

• 16.1. UK Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gynecology Drugs Market

• 17.1. Germany Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gynecology Drugs Market

• 18.1. France Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gynecology Drugs Market

• 19.1. Italy Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gynecology Drugs Market

• 20.1. Spain Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gynecology Drugs Market

• 21.1. Eastern Europe Gynecology Drugs Market Overview
• 21.2. Eastern Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gynecology Drugs Market

• 22.1. Russia Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gynecology Drugs Market

• 23.1. North America Gynecology Drugs Market Overview
• 23.2. North America Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gynecology Drugs Market

• 24.1. USA Gynecology Drugs Market Overview
• 24.2. USA Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gynecology Drugs Market

• 25.1. Canada Gynecology Drugs Market Overview
• 25.2. Canada Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gynecology Drugs Market

• 26.1. South America Gynecology Drugs Market Overview
• 26.2. South America Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gynecology Drugs Market

• 27.1. Brazil Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gynecology Drugs Market

• 28.1. Middle East Gynecology Drugs Market Overview
• 28.2. Middle East Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gynecology Drugs Market

• 29.1. Africa Gynecology Drugs Market Overview
• 29.2. Africa Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gynecology Drugs Market Competitive Landscape And Company Profiles

• 30.1. Gynecology Drugs Market Competitive Landscape
• 30.2. Gynecology Drugs Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Gynecology Drugs Market Other Major And Innovative Companies

• 31.1. Ferring Holding SA
• 31.2. TherapeuticsMD Inc.
• 31.3. Lupin Pharmaceuticals Inc.
• 31.4. Johnson & Johnson
• 31.5. Eli Lilly and Company
• 31.6. Bayer AG
• 31.7. Abbott Laboratories Ltd.
• 31.8. AstraZeneca
• 31.9. Amgen Inc.
• 31.10. Bristol-Myers Squibb Company
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Allergan plc
• 31.13. Sanofi S.A.
• 31.14. Coloplast A/S
• 31.15. Cipla Limited

32. Global Gynecology Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gynecology Drugs Market

34. Recent Developments In The Gynecology Drugs Market

35. Gynecology Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Gynecology Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gynecology Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gynecology Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer